Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Paratek Pharmaceuticals stock
Learn how to easily invest in Paratek Pharmaceuticals stock.
Paratek Pharmaceuticals Inc is a biotechnology business based in the US. Paratek Pharmaceuticals shares (PRTK) are listed on the NASDAQ and all prices are listed in US Dollars. Paratek Pharmaceuticals employs 207 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Paratek Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PRTK – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Paratek Pharmaceuticals stock price (NASDAQ: PRTK)Use our graph to track the performance of PRTK stocks over time.
Paratek Pharmaceuticals shares at a glance
|Latest market close||$1.96|
|52-week range||$1.60 - $7.02|
|50-day moving average||$2.04|
|200-day moving average||$3.64|
|Wall St. target price||$18.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.18|
Buy Paratek Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Paratek Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Paratek Pharmaceuticals price performance over time
|1 week (2022-06-27)||-4.85%|
|1 month (2022-06-01)||4.26%|
|3 months (2022-04-01)||-33.33%|
|6 months (2021-12-31)||N/A|
|1 year (2021-07-02)||-71.76%|
|2 years (2020-07-02)||-61.94%|
|3 years (2019-07-03)||4|
|5 years (2017-07-03)||24.2|
Paratek Pharmaceuticals financials
|Revenue TTM||$138.6 million|
|Gross profit TTM||$78.3 million|
|Return on assets TTM||-15.41%|
|Return on equity TTM||0%|
|Market capitalisation||$106.8 million|
TTM: trailing 12 months
Paratek Pharmaceuticals share dividends
We're not expecting Paratek Pharmaceuticals to pay a dividend over the next 12 months.
Have Paratek Pharmaceuticals's shares ever split?
Paratek Pharmaceuticals's shares were split on a 1:12 basis on 30 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Paratek Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Paratek Pharmaceuticals shares which in turn could have impacted Paratek Pharmaceuticals's share price.
Paratek Pharmaceuticals share price volatility
Over the last 12 months, Paratek Pharmaceuticals's shares have ranged in value from as little as $1.6 up to $7.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Paratek Pharmaceuticals's is 1.5749. This would suggest that Paratek Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Paratek Pharmaceuticals overview
Paratek Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co. , Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc.
Paratek Pharmaceuticals in the news
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals’ NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)
Frequently asked questionsWhat percentage of Paratek Pharmaceuticals is owned by insiders or institutions?
Currently 16.583% of Paratek Pharmaceuticals shares are held by insiders and 53.725% by institutions. How many people work for Paratek Pharmaceuticals?
Latest data suggests 207 work at Paratek Pharmaceuticals. When does the fiscal year end for Paratek Pharmaceuticals?
Paratek Pharmaceuticals's fiscal year ends in December. Where is Paratek Pharmaceuticals based?
Paratek Pharmaceuticals's address is: 75 Park Plaza, Boston, MA, United States, 02116 What is Paratek Pharmaceuticals's ISIN number?
Paratek Pharmaceuticals's international securities identification number is: US6993743029 What is Paratek Pharmaceuticals's CUSIP number?
Paratek Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 66987B103
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert